Results, Rhetoric, and Randomized Trials: The Case of Donepezil

Whether donepezil provides meaningful benefit to patients with Alzheimer's disease (AD) is controversial, but drug sales annually total billions of dollars. A review of data from published randomized clinical trials (RCTs) found rhetorical patterns that may encourage use of this drug.

[1]  Martin Knapp,et al.  Donepezil for the treatment of agitation in Alzheimer's disease. , 2007, The New England journal of medicine.

[2]  S. E. Black,et al.  Donepezil preserves cognition and global function in patients with severe Alzheimer disease , 2007, Neurology.

[3]  C. Elliott,et al.  Ghost Marketing: Pharmaceutical Companies and Ghostwritten Journal Articles , 2007, Perspectives in biology and medicine.

[4]  K. Marder.  Donepezil in patients with severe alzheimer’s disease , 2006, Current neurology and neuroscience reports.

[5]  M. Chren,et al.  Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.

[6]  Sture Eriksson,et al.  Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.

[7]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[8]  H. Feldman,et al.  Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial , 2005, International journal of geriatric psychiatry.

[9]  B. Seltzer,et al.  Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. , 2004, Archives of neurology.

[10]  Gordon H Guyatt,et al.  Users' guide to detecting misleading claims in clinical research reports , 2004, BMJ : British Medical Journal.

[11]  A. Jacobs.  Time for the ghosts to take on physical form , 2004, The Lancet.

[12]  C. Holmes,et al.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease , 2004, Neurology.

[13]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[14]  M. Boustani,et al.  Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2003, Annals of Internal Medicine.

[15]  Bruno Vellas,et al.  Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden , 2003, Journal of the American Geriatrics Society.

[16]  B. Oken.  Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[17]  P. Tariot,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.

[18]  R. Horton,et al.  Sponsorship, authorship and accountability. , 2001, Lakartidningen.

[19]  H. Feldman,et al.  A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.

[20]  Dirk Deleu,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.

[21]  B. Winblad,et al.  A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.

[22]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[23]  R. S. Doody, MD, PhD,et al.  Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[24]  R. Holman.  Seeing what you want to see in randomised controlled trials , 2000, BMJ : British Medical Journal.

[25]  K. Hasegawa,et al.  Clinical Efficacy and Safety of Donepezil on Cognitive and Global Function in Patients with Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[26]  T. Greenhalgh,et al.  Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data , 2000, BMJ : British Medical Journal.

[27]  S. G. Phillips,et al.  Whose article is it anyway? , 1999, The Lancet.

[28]  H.-J. Möller,et al.  The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 , 1999, Dementia and Geriatric Cognitive Disorders.

[29]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[30]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[31]  R. Horton.  The rhetoric of research , 1995, BMJ.

[32]  J. Segal,et al.  Strategies of influence in medical authorship. , 1993, Social science & medicine.

[33]  H. Brodaty,et al.  Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease , 2004, Drugs & aging.

[34]  S. Wiebe,et al.  Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons , 2003 .

[35]  R. Sperling,et al.  Donepezil therapy in clinical practice: a randomized crossover study. , 2000, Archives of neurology.

[36]  L. Friedhoff,et al.  The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. , 1996, Dementia.